Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Top Performing Drugs of 2021: A Monthly Series by PharmaShots
Top Performing Drugs of 2021: A Monthly Series by PharmaShots
The year 2021 witnessed the global approval of vaccines and drugs amid COVID-19. The disease has been dominating the headlines from the last two years. No one is amazed that COVID vaccines and drugs find a place in top selling drugs this time. Pfizer & BioNTech’s Comirnaty took the first position with $36B revenue and…
April 28, 2022
Insights+ The US FDA New Drug Approvals in March 2022
Insights+: The US FDA New Drug Approvals in March 2022
The US FDA has approved 9 NDAs and 1 BLAs in Mar 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 20 novel products in 2022 In Mar 2022, the major highlights drugs were Adlarity for Alzheimer's Disease, Rinvoq for Ulcerative Colitis, Ztalmy for CDKL5 Deficiency Disorder…
April 21, 2022
Disease of the Month: Chagas Disease (American Trypanosomiasis)
Disease of the Month: Chagas Disease (American Trypanosomiasis)
INTRODUCTION Chagas disease also known by the name American trypanosomiasis, is a zoonotic infection, caused by protozoan flagellate Trypanosoma cruzi (kissing bugs). It is potentially a life-threatening infection transmitted to people and animals from the feces of blood-sucking bugs which belong to the subfamily of Triatominae2. Among all the vectors, Rhodnius proxilus, Panstrongylus megistus, and…
April 14, 2022
Insights+ Key Biosimilars Events of March 2022
Insights+ Key Biosimilars Events of March 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab)…
April 7, 2022
PharmaShots' Key Highlights of First Quarter 2022
PharmaShots’ Key Highlights of First Quarter 2022
The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…
March 31, 2022
Insights+: Trends in the US FDA Oncology Approvals (2011-2021)
Insights+: Trends in the US FDA Oncology Approvals (2011-2021)
A record number of new oncology drugs have been approved every year, addressing the unique challenges faced by cancer patients. However, oncology is always a thought-provoking area for research and development despite having numerous approved therapies. Many pharmaceuticals are working on oncology and are trying to address the complexity of the disease. We have global…
March 24, 2022
Insight+_Senior Editor
Insights+: The US FDA New Drug Approvals in February 2022
The US FDA has approved 4 NDAs and 1 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 10 novel products in 2022 In Feb 2022, the major highlights drugs were Enjaymo for cold agglutinin disease, Fleqsuvy for spasticity associated with multiple sclerosis,…
March 17, 2022
Insights+ Key Biosimilars Events of February 2022
Insights+ Key Biosimilars Events of February 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of February, Biocon acquired Viatris’ biosimilars assets for ~$3.335B,…
March 3, 2022
Insights+ The US FDA New Drug Approvals in January 2022
Insights+: The US FDA New Drug Approvals in January 2022
The US FDA has approved 3 NDAs and 2 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 5 novel products in 2022 In Jan 2022, the major highlights were Quviviq's approval for insomnia, Cibinqo for atopic dermatitis, Kimmtrak for unresectable or metastatic…
February 17, 2022
Insights+ Key Biosimilars Events of January 2022
Insights+ Key Biosimilars Events of January 2022
Insights+ Key Biosimilars Events of January 2022 Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of January,…
February 3, 2022
Load more